Viva Biotech invests in limited partnership fund

Viva Biotech Holdings (HKEX: 1873) announced that its wholly-owned subsidiary, Hangzhou Viva Zongchen, will invest RMB25.0 million in a newly established limited partnership fund. The fund, named Nanjing Honghui Weitai Venture Capital Fund Partnership (Limited Partnership), will focus on early-stage biopharmaceutical development projects. Viva Biotech's non-executive director, Wang Stephen Hui, has an indirect interest in Nanjing Ruihong, the fund's general partner, triggering connected transaction reporting requirements. The investment will enable the Company to accumulate experiences for future collaboration with prospective investors and pharmaceutical start-ups and broaden the Group's industry networks. The company will finance its capital contribution through internal resources.